Literature DB >> 12898488

HIV postexposure prophylaxis practices by US ED practitioners.

Roland C Merchant1, Reza Keshavarz.   

Abstract

To determine how often US ED practitioners have prescribed HIV post-exposure prophylaxis (HIV PEP) and to discern how willing they are to offer it to patients, the authors surveyed 600 ED practitioners attending a national conference. According to their self-report, 11% had taken HIV PEP themselves. Sixty-eight percent had prescribed HIV PEP at some time. Of these, 92% had treated needlestick-injured health care workers, 48% sexual assault survivors, and 49% nonhealth care needlestick-injured persons. ED practitioners were more willing to offer HIV PEP after exposures to HIV-infected or high-risk sources than unknown or low- risk sources, as well as after sexual assault than consensual sex. Female practitioners, those who had themselves taken HIV PEP, resident physicians, and ED practitioners with fewer than 6 years of clinical practice were generally more apt to offer HIV PEP. Educational campaigns appear to be necessary to help ED practitioners determine when HIV PEP is appropriate.

Entities:  

Mesh:

Year:  2003        PMID: 12898488     DOI: 10.1016/s0735-6757(02)42242-5

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  2 in total

1.  HIV medical providers' perceptions of the use of antiretroviral therapy as nonoccupational postexposure prophylaxis in 2 major metropolitan areas.

Authors:  Allan E Rodríguez; Amanda D Castel; Carrigan L Parish; Sarah Willis; Daniel J Feaster; Michael Kharfen; Gabriel A Cardenas; Kira Villamizar; Michael Kolber; Liliana Vázquez-Rivera; Lisa R Metsch
Journal:  J Acquir Immune Defic Syndr       Date:  2013-11-01       Impact factor: 3.731

2.  Predictors of the initiation of HIV postexposure prophylaxis in Rhode Island emergency departments.

Authors:  Roland C Merchant; Kenneth H Mayer; Bruce M Becker; Allison K Delong; Joseph W Hogan
Journal:  AIDS Patient Care STDS       Date:  2008-01       Impact factor: 5.078

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.